RESUMO
We present a case of ureterovesical stenosis that developed in 2 of 203 renal transplant patients operated between 1997 and 2005 in our department. In the current case, an ureterovesical region tumor was identified 1.5 years after renal transplantation, while being operated for the correction of ureterovesical stenosis. This report sought to remind physicians about the possibility of a malignancy in patients with ureterovesical stenosis following renal transplantation.
Assuntos
Transplante de Rim/efeitos adversos , Neoplasias Ureterais/patologia , Neoplasias da Bexiga Urinária/patologia , Adulto , Antimetabólitos Antineoplásicos/uso terapêutico , Carcinoma de Células de Transição/diagnóstico por imagem , Carcinoma de Células de Transição/tratamento farmacológico , Carcinoma de Células de Transição/patologia , Desoxicitidina/análogos & derivados , Desoxicitidina/uso terapêutico , Humanos , Incidência , Masculino , Diálise Peritoneal Ambulatorial Contínua , Radiografia , Fatores de Tempo , Neoplasias Ureterais/diagnóstico por imagem , Neoplasias Ureterais/epidemiologia , Neoplasias da Bexiga Urinária/diagnóstico por imagem , Neoplasias da Bexiga Urinária/epidemiologia , GencitabinaRESUMO
OBJECTIVE: To evaluate the effectiveness and tolerability of intravesical epirubicin treatment to prevent recurrence and progression of superficial bladder tumor after TUR. METHODS: 44 patients with superficial bladder tumor, 28 primary and 16 recurrent cases were given 50 mg intravesical epirubicin once a week for 8 weeks after TUR. Recurrent cases had not been treated by any intravesical agent before. Follow-up was done by cystoscopy, urine cytology and random biopsies. RESULTS: Local recurrence after treatment was found in 14.28% and 18.75%, and recurrence in another area was found in 21.42% and 31.25% of the primary and recurrent tumor groups respectively. Total recurrence in both groups was 40.91%. No systemic toxicity was observed and local side effects were treated symptomatically. CONCLUSION: Intravesical epirubicin after TUR for superficial bladder tumors especially for the primary ones, is a reliable method that provides effective prophylaxis with tolerable side effects.
